FEATURED COMPANIES
- Abbott Laboratories
- Caliper Life Sciences
- Cepheid
- elveflow
- Fluidigm Corporation
- Illumina, Inc.
- MORE
The global microfluidics market size is expected to reach USD 31.6 billion by 2027, according to this report registering an 11.3% CAGR over the forecast period. Demand for microfluidic-based devices is expected to surge owing to introduction of novel technologies such as digital microfluidics. These techniques allow on-chip biochemical analysis, thereby driving adoption.
Rise in the adoption of microfluidics for point-of-care diagnostics is expected to have a significant impact on market growth. Industry players such as Abbott, Roche, and Danaher have already incorporated this technology in their existing diagnostic devices and are exploring the scope of digital microfluidics. For instance, Philips’ Minicare I-20 handheld device provides accurate and rapid results for the diagnosis of heart attacks.
Large investments targeted toward the development of microfluidics and promoting their adoption are expected to create opportunities for the expansion for automated as well as miniature devices. For instance, according to an article published in 2018, there have been large-scale investments in “sample-to-answer” microfluidic automated testing in recent years.
Microfluidics has not only been proven beneficial in biological bench-work but also several medical and pharmaceutical applications, including diagnosis of infectious diseases and treatment of cancer. The technology aids in the fabrication of functional living tissues and artificial organs. Companies such as Abbott, Roche, Cepheid, and Becton, Dickinson and Company (BD) are integrating such technologies with in-vitro diagnostics (IVD). Samsung LABGEOPT10 and Abbott i-STAT are examples of single-step blood glucose testing assays that can work on a small sample volume (a single blood drop).
Further key findings from the study suggest:
Rise in the adoption of microfluidics for point-of-care diagnostics is expected to have a significant impact on market growth. Industry players such as Abbott, Roche, and Danaher have already incorporated this technology in their existing diagnostic devices and are exploring the scope of digital microfluidics. For instance, Philips’ Minicare I-20 handheld device provides accurate and rapid results for the diagnosis of heart attacks.
Large investments targeted toward the development of microfluidics and promoting their adoption are expected to create opportunities for the expansion for automated as well as miniature devices. For instance, according to an article published in 2018, there have been large-scale investments in “sample-to-answer” microfluidic automated testing in recent years.
Microfluidics has not only been proven beneficial in biological bench-work but also several medical and pharmaceutical applications, including diagnosis of infectious diseases and treatment of cancer. The technology aids in the fabrication of functional living tissues and artificial organs. Companies such as Abbott, Roche, Cepheid, and Becton, Dickinson and Company (BD) are integrating such technologies with in-vitro diagnostics (IVD). Samsung LABGEOPT10 and Abbott i-STAT are examples of single-step blood glucose testing assays that can work on a small sample volume (a single blood drop).
Further key findings from the study suggest:
- The medical/healthcare segment dominated the market by technology owing to rise in demand for new molecular diagnostic tests with enhanced sensitivities, shorter turnaround time, and increased accuracy at minimal costs
- PCR & RT-PCR were the largest revenue-generating medical technology in 2019 and the segment is expected to retain its lead throughout the forecast period. Digital PCR in combination with a microfluidic device allows a large amount of PCR reaction mix to be distributed into nanoliter-sized volumes automatically
- The organs-on-chips application segment is expected to register the fastest CAGR throughout the forecast period. The method can potentially reduce the failure rate in drug development pipelines, thereby reducing the time and money associated with drug development
- by material, polydimethylsiloxane (PDMS) accounted for the largest revenue share in 2019. The material is used to fabricate microfluidic-based devices because of its nontoxicity, robustness, optical transparency, permeability, biocompatibility, elastomeric features, and low cost.
- North America dominated the global microfluidics market in 2019 and is expected to retain its dominance over the analysis period. Local presence of leading players, availability of funds and research capital, and launch of novel sample volume screening technologies drives the North America market
- Asia Pacific is expected to witness the fastest growth owing to rise in aging population, demand for point-of-care diagnostic tests, and presence of academic institutions such as the Institute of Microchemical Technology (IMT), Japan, that are focused on microfluidic-based research
- Illumina, Inc., PerkinElmer, Inc., Agilent Technologies, Inc., Danaher Corporation, Bio-Rad Laboratories, Inc., Life Technologies Corporation, Abbott Laboratories, F. Hoffmann-La Roche Ltd, and Fluidigm Corporation are some of the key players operating in the global market
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Abbott Laboratories
- Caliper Life Sciences
- Cepheid
- elveflow
- Fluidigm Corporation
- Illumina, Inc.
- MORE
Chapter 1 Executive Summary
1.1 Market Snapshot
Chapter 2 Research Methodology
2.1 Information Procurement
2.2 Information Or Data Analysis
2.3 Market Formulation & Validation
Chapter 3 Microfluidics Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3 Penetration & Growth Prospect Mapping For Materials, 2019
3.4 Microfluidics Market-SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
3.5 Industry Analysis – Porter’s
3.6 Market Driver Analysis
3.6.1 Increasing Demand For Low Volume Sample Analysis
3.6.2 Growing Penetration Of Microfluidics In Diagnostics Market
3.6.3 Introduction Of Advanced Technologies
3.7 Market Restraint Analysis
3.7.1 High Operational Cost
3.7.2 Interfacing And Integration
3.7.3 Complex Fabrication Process
3.8 Market Opportunity Analysis
3.8.1 Investments By Companies In Technological Advancements
3.8.2 Growing Adoption Of Point-Of-Care (Poc) Tests
3.8.3 Expansion Of Application Scope For Microfluidics Technology
3.9 Manufacturing Practices & Trends
3.9.1 Photomask Fabrication
3.9.2 Photolithography Process
3.9.2.1 Methacrylate Coating
3.9.2.2 UV Exposure
3.9.2.3 Washing
3.9.3 Molding Microfluidic Chips
3.9.3.1 Soft Lithography
3.9.3.2 Soft Embossing
3.9.4 Microfabrication
Chapter 4 Microfluidics Market Categorization: Technology Estimates & Trend Analysis
4.1 Microfluidics Market: Technology Movement Analysis
4.2 Medical/Healthcare
4.2.1 Microfluidics Market For Medical/Healthcare, 2016 - 2027 (USD Million)
4.2.2 Pcr
4.2.2.1 Microfluidics Market For Pcr, 2016 - 2027 (USD Million)
4.2.3 Gel Electrophoresis
4.2.3.1 Microfluidics Market For Gel Electrophoresis, 2016 - 2027 (USD Million)
4.2.4 Microarrays
4.2.4.1 Microfluidics Market For Microarrays, 2016 - 2027 (USD Million)
4.2.5 Enzyme-Linked Immunosorbent Assay (Elisa)
4.2.5.1 Microfluidics Market For Elisa, 2016 - 2027 (USD Million)
4.2.6 Others
4.2.6.1 Microfluidics Market For Other Technologies, 2016 - 2027 (USD Million)
4.3 Non-Medical
4.3.1 Non-Medical Microfluidics Market, 2016 - 2027 (USD Million)
Chapter 5 Microfluidics Market Categorization: Material Estimates & Trend Analysis
5.1 Microfluidics Market: Material Movement Analysis
5.2 Silicon
5.2.1 Microfluidics Market For Silicon, 2016 - 2027 (USD Million)
5.3 Glass
5.3.1 Microfluidics Market For Glass, 2016 - 2027 (USD Million)
5.4 Polymer
5.4.1 Microfluidics Market For Polymer, 2016 - 2027 (USD Million)
5.5 Polydimethylsiloxane (Pdms)
5.5.1 Microfluidics Market For Pdms, 2016 - 2027 (USD Million)
5.6 Others
5.6.1 Microfluidics Market For Other Materials, 2016 - 2027 (USD Million)
Chapter 6 Microfluidics Market Categorization: Application Estimates & Trend Analysis
6.1 Microfluidics Market: Application Movement Analysis
6.2 Lab-On-A-Chip Market, 2016 - 2027 (USD Million)
6.2.1 Medical
6.2.1.1 Medical Lab-On-A-Chip Market, 2016 - 2027 (USD Million)
6.2.2 Non-Medical
6.2.2.1 Non-Medical Lab-On-A-Chip Market, 2016 - 2027 (USD Million)
6.3 Organs-On-Chips Market, 2016 - 2027 (USD Million)
6.3.1 Medical
6.3.1.1 Medical Organs-On-Chips Market, 2016 - 2027 (USD Million)
6.4 Continuous Flow Microfluidics Market, 2016 - 2027 (USD Million)
6.4.1 Medical
6.4.1.1 Medical Continuous Flow Microfluidics Market, 2016 - 2027 (USD Million)
6.4.2 Non-Medical
6.4.2.1 Non-Medical Continuous Flow Microfluidics Market, 2016 - 2027 (USD Million)
6.5 Optofluidics And Microfluidics Market, 2016 - 2027 (USD Million)
6.5.1 Medical
6.5.1.1 Medical Optofluidics And Microfluidics Market, 2016 - 2027 (USD Million)
6.5.2 Non-Medical
6.5.2.1 Non-Medical Optofluidics And Microfluidics Market, 2016 - 2027 (USD Million)
6.6 Acoustofluidics And Microfluidics Market, 2016 - 2027 (USD Million)
6.6.1 Medical
6.6.1.1 Medical Acoustofluidics And Microfluidics Market, 2016 - 2027 (USD Million)
6.6.2 Non-Medical
6.6.2.1 Non-Medical Acoustofluidics And Microfluidics Market, 2016 - 2027 (USD Million)
6.7 Electrophoresis And Microfluidics Market, 2016 - 2027 (USD Million)
6.7.1 Medical
6.7.1.1 Medical Electrophoresis And Microfluidics Market, 2016 - 2027 (USD Million)
6.7.2 Non-Medical
6.7.2.1 Non-Medical Electrophoresis And Microfluidics Market, 2016 - 2027 (USD Million)
Chapter 7 Microfluidics Market Categorization: Regional Estimates & Trend Analysis, By Technology, Materials, And Application
7.1 Microfluidics Market Share By Regional, 2019 & 2027
7.2 North America
7.2.1 North America Microfluidics Market, 2016 - 2027 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. Microfluidics Market, 2016 - 2027 (USD Million)
7.2.3 Canada
7.2.3.1 Canada Microfluidics Market, 2016 - 2027 (USD Million)
7.3 Europe
7.3.1 Europe Microfluidics Market, 2016 - 2027 (USD Million)
7.3.2 Germany
7.3.2.1 Germany Microfluidics Market, 2016 - 2027 (USD Million)
7.3.3 France
7.3.3.1 France Microfluidics Market, 2016 - 2027 (USD Million)
7.3.4 U.K.
7.3.4.1 U.K. Microfluidics Market, 2016 - 2027 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific Microfluidics Market, 2016 - 2027 (USD Million)
7.4.2 Japan
7.4.2.1 Japan Microfluidics Market, 2016 - 2027 (USD Million)
7.4.3 China
7.4.3.1 China Microfluidics Market, 2016 - 2027 (USD Million)
7.4.4 India
7.4.4.1 India Microfluidics Market, 2016 - 2027 (USD Million)
7.5 Latin America
7.5.1 Latin America Microfluidics Market, 2016 - 2027 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil Microfluidics Market, 2016 - 2027 (USD Million)
7.5.3 Mexico
7.5.3.1 Mexico Microfluidics Market, 2016 - 2027 (USD Million)
7.6 Middle East & Africa (Mea)
7.6.1 Mea Microfluidics Market, 2016 - 2027 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa Microfluidics Market, 2016 - 2027 (USD Million)
Chapter 8 Competitive Landscape
8.1 Strategy Framework
8.2 Market Participant Categorization
8.3 Company Profiles
8.3.1 Illumina, Inc.
8.3.1.1 Company Overview
8.3.1.2 Financial Performance
8.3.1.3 Product Benchmarking
8.3.1.4 Strategic Initiatives
8.3.2 Agilent Technologies, Inc.
8.3.2.1 Company Overview
8.3.2.2 Financial Performance
8.3.2.3 Product Benchmarking
8.3.2.4 Strategic Initiatives
8.3.3 Perkinelmer, Inc.
8.3.3.1 Company Overview
8.3.3.1.1 Caliper Life Sciences
8.3.3.2 Financial Performance
8.3.3.3 Product Benchmarking
8.3.3.4 Strategic Initiatives
8.3.4 Danaher
8.3.4.1 Company Overview
8.3.4.1.1 Leica Biosystems Nussloch Gmbh
8.3.4.1.2 Cepheid
8.3.4.2 Financial Performance
8.3.4.2.1 Financial Performance (Leica Biosystems Nussloch Gmbh)
8.3.4.2.2 Financial Performance (Cepheid)
8.3.4.3 Product Benchmarking
8.3.4.3.1 Product Benchmarking: Cepheid
8.3.4.4 Strategic Initiatives
8.3.5 Life Technologies Corporation
8.3.5.1 Company Overview
8.3.5.2 Financial Performance
8.3.5.3 Product Benchmarking
8.3.5.4 Strategic Initiatives
8.3.6 Bio-Rad Laboratories, Inc.
8.3.6.1 Company Overview
8.3.6.2 Financial Performance
8.3.6.3 Product Benchmarking
8.3.6.4 Strategic Initiatives
8.3.7 Abbott Laboratories
8.3.7.1 Company Overview
8.3.7.2 Financial Performance
8.3.7.3 Product Benchmarking
8.3.7.4 Strategic Initiatives
8.3.8 F. Hoffmann-La Roche Ltd
8.3.8.1 Company Overview
8.3.8.1.1 Genentech, Inc.
8.3.8.2 Financial Performance
8.3.8.3 Product Benchmarking
8.3.8.4 Strategic Initiatives
8.3.9 Fluidigm Corporation
8.3.9.1 Company Overview
8.3.9.2 Financial Performance
8.3.9.3 Product Benchmarking
8.3.9.4 Strategic Initiatives
8.3.10 thermofisher Scientific
8.3.10.1 Company Overview
8.3.10.2 Financial Performance
8.3.10.3 Product Benchmarking
8.3.10.4 Strategic Initiatives
8.3.11 qiagen N.V.
8.3.11.1 Company Overview
8.3.11.2 Financial Performance
8.3.11.3 Product Benchmarking
8.3.11.4 Strategic Initiatives
8.3.12 biomérieux
8.3.12.1 Company Overview
8.3.12.2 Financial Performance
8.3.12.3 Product Benchmarking
8.3.12.4 Strategic Initiatives
8.3.13 elveflow
8.3.13.1 Company Overview
8.3.13.2 Financial Performance
8.3.13.3 Product Benchmarking
8.3.13.4 Strategic Initiatives
8.3.14 cellix Ltd.
8.3.14.1 Company Overview
8.3.14.2 Financial Performance
8.3.14.3 Product Benchmarking
8.3.14.4 Strategic Initiatives
8.3.15 micronit Micro Technologies B.V.
8.3.15.1 Company Overview
8.3.15.2 Financial Performance
8.3.15.3 Product Benchmarking
8.3.15.4 Strategic Initiatives
1.1 Market Snapshot
Chapter 2 Research Methodology
2.1 Information Procurement
2.2 Information Or Data Analysis
2.3 Market Formulation & Validation
Chapter 3 Microfluidics Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3 Penetration & Growth Prospect Mapping For Materials, 2019
3.4 Microfluidics Market-SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
3.5 Industry Analysis – Porter’s
3.6 Market Driver Analysis
3.6.1 Increasing Demand For Low Volume Sample Analysis
3.6.2 Growing Penetration Of Microfluidics In Diagnostics Market
3.6.3 Introduction Of Advanced Technologies
3.7 Market Restraint Analysis
3.7.1 High Operational Cost
3.7.2 Interfacing And Integration
3.7.3 Complex Fabrication Process
3.8 Market Opportunity Analysis
3.8.1 Investments By Companies In Technological Advancements
3.8.2 Growing Adoption Of Point-Of-Care (Poc) Tests
3.8.3 Expansion Of Application Scope For Microfluidics Technology
3.9 Manufacturing Practices & Trends
3.9.1 Photomask Fabrication
3.9.2 Photolithography Process
3.9.2.1 Methacrylate Coating
3.9.2.2 UV Exposure
3.9.2.3 Washing
3.9.3 Molding Microfluidic Chips
3.9.3.1 Soft Lithography
3.9.3.2 Soft Embossing
3.9.4 Microfabrication
Chapter 4 Microfluidics Market Categorization: Technology Estimates & Trend Analysis
4.1 Microfluidics Market: Technology Movement Analysis
4.2 Medical/Healthcare
4.2.1 Microfluidics Market For Medical/Healthcare, 2016 - 2027 (USD Million)
4.2.2 Pcr
4.2.2.1 Microfluidics Market For Pcr, 2016 - 2027 (USD Million)
4.2.3 Gel Electrophoresis
4.2.3.1 Microfluidics Market For Gel Electrophoresis, 2016 - 2027 (USD Million)
4.2.4 Microarrays
4.2.4.1 Microfluidics Market For Microarrays, 2016 - 2027 (USD Million)
4.2.5 Enzyme-Linked Immunosorbent Assay (Elisa)
4.2.5.1 Microfluidics Market For Elisa, 2016 - 2027 (USD Million)
4.2.6 Others
4.2.6.1 Microfluidics Market For Other Technologies, 2016 - 2027 (USD Million)
4.3 Non-Medical
4.3.1 Non-Medical Microfluidics Market, 2016 - 2027 (USD Million)
Chapter 5 Microfluidics Market Categorization: Material Estimates & Trend Analysis
5.1 Microfluidics Market: Material Movement Analysis
5.2 Silicon
5.2.1 Microfluidics Market For Silicon, 2016 - 2027 (USD Million)
5.3 Glass
5.3.1 Microfluidics Market For Glass, 2016 - 2027 (USD Million)
5.4 Polymer
5.4.1 Microfluidics Market For Polymer, 2016 - 2027 (USD Million)
5.5 Polydimethylsiloxane (Pdms)
5.5.1 Microfluidics Market For Pdms, 2016 - 2027 (USD Million)
5.6 Others
5.6.1 Microfluidics Market For Other Materials, 2016 - 2027 (USD Million)
Chapter 6 Microfluidics Market Categorization: Application Estimates & Trend Analysis
6.1 Microfluidics Market: Application Movement Analysis
6.2 Lab-On-A-Chip Market, 2016 - 2027 (USD Million)
6.2.1 Medical
6.2.1.1 Medical Lab-On-A-Chip Market, 2016 - 2027 (USD Million)
6.2.2 Non-Medical
6.2.2.1 Non-Medical Lab-On-A-Chip Market, 2016 - 2027 (USD Million)
6.3 Organs-On-Chips Market, 2016 - 2027 (USD Million)
6.3.1 Medical
6.3.1.1 Medical Organs-On-Chips Market, 2016 - 2027 (USD Million)
6.4 Continuous Flow Microfluidics Market, 2016 - 2027 (USD Million)
6.4.1 Medical
6.4.1.1 Medical Continuous Flow Microfluidics Market, 2016 - 2027 (USD Million)
6.4.2 Non-Medical
6.4.2.1 Non-Medical Continuous Flow Microfluidics Market, 2016 - 2027 (USD Million)
6.5 Optofluidics And Microfluidics Market, 2016 - 2027 (USD Million)
6.5.1 Medical
6.5.1.1 Medical Optofluidics And Microfluidics Market, 2016 - 2027 (USD Million)
6.5.2 Non-Medical
6.5.2.1 Non-Medical Optofluidics And Microfluidics Market, 2016 - 2027 (USD Million)
6.6 Acoustofluidics And Microfluidics Market, 2016 - 2027 (USD Million)
6.6.1 Medical
6.6.1.1 Medical Acoustofluidics And Microfluidics Market, 2016 - 2027 (USD Million)
6.6.2 Non-Medical
6.6.2.1 Non-Medical Acoustofluidics And Microfluidics Market, 2016 - 2027 (USD Million)
6.7 Electrophoresis And Microfluidics Market, 2016 - 2027 (USD Million)
6.7.1 Medical
6.7.1.1 Medical Electrophoresis And Microfluidics Market, 2016 - 2027 (USD Million)
6.7.2 Non-Medical
6.7.2.1 Non-Medical Electrophoresis And Microfluidics Market, 2016 - 2027 (USD Million)
Chapter 7 Microfluidics Market Categorization: Regional Estimates & Trend Analysis, By Technology, Materials, And Application
7.1 Microfluidics Market Share By Regional, 2019 & 2027
7.2 North America
7.2.1 North America Microfluidics Market, 2016 - 2027 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. Microfluidics Market, 2016 - 2027 (USD Million)
7.2.3 Canada
7.2.3.1 Canada Microfluidics Market, 2016 - 2027 (USD Million)
7.3 Europe
7.3.1 Europe Microfluidics Market, 2016 - 2027 (USD Million)
7.3.2 Germany
7.3.2.1 Germany Microfluidics Market, 2016 - 2027 (USD Million)
7.3.3 France
7.3.3.1 France Microfluidics Market, 2016 - 2027 (USD Million)
7.3.4 U.K.
7.3.4.1 U.K. Microfluidics Market, 2016 - 2027 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific Microfluidics Market, 2016 - 2027 (USD Million)
7.4.2 Japan
7.4.2.1 Japan Microfluidics Market, 2016 - 2027 (USD Million)
7.4.3 China
7.4.3.1 China Microfluidics Market, 2016 - 2027 (USD Million)
7.4.4 India
7.4.4.1 India Microfluidics Market, 2016 - 2027 (USD Million)
7.5 Latin America
7.5.1 Latin America Microfluidics Market, 2016 - 2027 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil Microfluidics Market, 2016 - 2027 (USD Million)
7.5.3 Mexico
7.5.3.1 Mexico Microfluidics Market, 2016 - 2027 (USD Million)
7.6 Middle East & Africa (Mea)
7.6.1 Mea Microfluidics Market, 2016 - 2027 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa Microfluidics Market, 2016 - 2027 (USD Million)
Chapter 8 Competitive Landscape
8.1 Strategy Framework
8.2 Market Participant Categorization
8.3 Company Profiles
8.3.1 Illumina, Inc.
8.3.1.1 Company Overview
8.3.1.2 Financial Performance
8.3.1.3 Product Benchmarking
8.3.1.4 Strategic Initiatives
8.3.2 Agilent Technologies, Inc.
8.3.2.1 Company Overview
8.3.2.2 Financial Performance
8.3.2.3 Product Benchmarking
8.3.2.4 Strategic Initiatives
8.3.3 Perkinelmer, Inc.
8.3.3.1 Company Overview
8.3.3.1.1 Caliper Life Sciences
8.3.3.2 Financial Performance
8.3.3.3 Product Benchmarking
8.3.3.4 Strategic Initiatives
8.3.4 Danaher
8.3.4.1 Company Overview
8.3.4.1.1 Leica Biosystems Nussloch Gmbh
8.3.4.1.2 Cepheid
8.3.4.2 Financial Performance
8.3.4.2.1 Financial Performance (Leica Biosystems Nussloch Gmbh)
8.3.4.2.2 Financial Performance (Cepheid)
8.3.4.3 Product Benchmarking
8.3.4.3.1 Product Benchmarking: Cepheid
8.3.4.4 Strategic Initiatives
8.3.5 Life Technologies Corporation
8.3.5.1 Company Overview
8.3.5.2 Financial Performance
8.3.5.3 Product Benchmarking
8.3.5.4 Strategic Initiatives
8.3.6 Bio-Rad Laboratories, Inc.
8.3.6.1 Company Overview
8.3.6.2 Financial Performance
8.3.6.3 Product Benchmarking
8.3.6.4 Strategic Initiatives
8.3.7 Abbott Laboratories
8.3.7.1 Company Overview
8.3.7.2 Financial Performance
8.3.7.3 Product Benchmarking
8.3.7.4 Strategic Initiatives
8.3.8 F. Hoffmann-La Roche Ltd
8.3.8.1 Company Overview
8.3.8.1.1 Genentech, Inc.
8.3.8.2 Financial Performance
8.3.8.3 Product Benchmarking
8.3.8.4 Strategic Initiatives
8.3.9 Fluidigm Corporation
8.3.9.1 Company Overview
8.3.9.2 Financial Performance
8.3.9.3 Product Benchmarking
8.3.9.4 Strategic Initiatives
8.3.10 thermofisher Scientific
8.3.10.1 Company Overview
8.3.10.2 Financial Performance
8.3.10.3 Product Benchmarking
8.3.10.4 Strategic Initiatives
8.3.11 qiagen N.V.
8.3.11.1 Company Overview
8.3.11.2 Financial Performance
8.3.11.3 Product Benchmarking
8.3.11.4 Strategic Initiatives
8.3.12 biomérieux
8.3.12.1 Company Overview
8.3.12.2 Financial Performance
8.3.12.3 Product Benchmarking
8.3.12.4 Strategic Initiatives
8.3.13 elveflow
8.3.13.1 Company Overview
8.3.13.2 Financial Performance
8.3.13.3 Product Benchmarking
8.3.13.4 Strategic Initiatives
8.3.14 cellix Ltd.
8.3.14.1 Company Overview
8.3.14.2 Financial Performance
8.3.14.3 Product Benchmarking
8.3.14.4 Strategic Initiatives
8.3.15 micronit Micro Technologies B.V.
8.3.15.1 Company Overview
8.3.15.2 Financial Performance
8.3.15.3 Product Benchmarking
8.3.15.4 Strategic Initiatives
Note: Product cover images may vary from those shown
- Illumina, Inc.
- Agilent Technologies, Inc.
- Perkinelmer, Inc.
- Caliper Life Sciences
- Danaher
- Leica Biosystems Nussloch Gmbh
- Cepheid
- Life Technologies Corporation
- Bio-Rad Laboratories, Inc.
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd
- Genentech, Inc.
- Fluidigm Corporation
- thermofisher Scientific
- qiagen N.V.
- biomérieux
- elveflow
- cellix Ltd.
- micronit Micro Technologies B.V.
Note: Product cover images may vary from those shown
LOADING...
